Indirect comparisons of oral fingolimod versus natalizumab and cladribine for the treatment of relapsing-remitting multiple sclerosis based on data from FREEDOMS, AFFIRM and CLARITY

被引：0
|
作者：
Nixon, R.
Eckert, B.
Cutter, G.
Mercier, F.
Francis, G.
Kappos, L.
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Novartis Inst Biomed Res Inc, Cambridge, MA USA
[5] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [31] Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice
    Alcala-Vicente, Carmen
    Perez-Miralles, Francisco C.
    Gascon-Gimenez, Francisco
    Bosca-Blasco, Isabel
    Navarre-Gimeno, Arantxa
    Coret-Ferrer, Francisco
    Casanova-Estruch, Bonaventura
    REVISTA DE NEUROLOGIA, 2017, 64 (10) : 445 - 453
  • [32] Oral simvastatin treatment in relapsing-remitting multiple sclerosis
    Vollmer, T
    Key, L
    Durkalski, V
    Tyor, W
    Corboy, J
    Markovic-Plese, S
    Preiningerova, J
    Rizzo, M
    Singh, L
    LANCET, 2004, 363 (9421): : 1607 - 1608
  • [33] REGIONAL EFFICACY OF NATALIZUMAB TREATMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
    Doshi, Anisha
    Voysey, Zanna
    Bunting, Eva
    Malik, Muzaffar
    Rashid, Waqar
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11):
  • [34] Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod
    Gasperini, Claudio
    Ruggieri, Serena
    Mancinelli, Chiara Rosa
    Pozzilli, Carlo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2013, 9 : 73 - 85
  • [35] MULTIPLE THERAPEUTIC DILEMMA STEP FURTHER WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS FOR THE FIRST LINE TREATMENT IS INEFFECTIVE: NATALIZUMAB AND FINGOLIMOD?
    Lovas Gabor
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2014, 67 (3-4): : 141 - 141
  • [36] Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lienert, C.
    Benkert, P.
    Beer, S.
    Hanni, P.
    Pardini, M.
    D'Souza, M.
    Derfuss, T.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    SWISS MEDICAL WEEKLY, 2016, 146 : 49S - 49S
  • [37] Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lienert, C.
    Benkert, P.
    Beer, S.
    Hanni, P.
    Pardini, M.
    D'Souza, M.
    Derfuss, T.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 627 - 627
  • [38] Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
    Kalincik, Tomas
    Brown, J. William L.
    Robertson, Neil
    Willis, Mark
    Scolding, Neil
    Rice, Claire M.
    Wilkins, Alastair
    Pearson, Owen
    Ziemssen, Tjalf
    Hutchinson, Michael
    McGuigan, Christopher
    Jokubaitis, Vilija
    Spelman, Tim
    Horakova, Dana
    Havrdova, Eva
    Trojano, Maria
    Izquierdo, Guillermo
    Lugaresi, Alessandra
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Grammond, Pierre
    Alroughani, Raed
    Pucci, Eugenio
    Sola, Patrizia
    Hupperts, Raymond
    Lechner-Scott, Jeannette
    Terzi, Murat
    Van Pesch, Vincent
    Rozsa, Csilla
    Grand'Maison, Francois
    Boz, Cavit
    Granella, Franco
    Slee, Mark
    Spitaleri, Daniele
    Olascoaga, Javier
    Bergamaschi, Roberto
    Verheul, Freek
    Vucic, Steve
    McCombe, Pamela
    Hodgkinson, Suzanne
    Sanchez-Menoyo, Jose Luis
    Ampapa, Radek
    Simo, Magdolna
    Csepany, Tunde
    Ramo, Cristina
    Cristiano, Edgardo
    Barnett, Michael
    Butzkueven, Helmut
    Coles, Alasdair
    LANCET NEUROLOGY, 2017, 16 (04): : 271 - 281
  • [39] Fingolimod: A potential first-in-class oral therapy for the treatment of relapsing-remitting multiple sclerosis
    Sobieraj, Diana M.
    FORMULARY, 2010, 45 (08) : 245 - 251
  • [40] Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Cohort Study
    Hernandez-Preciado, Martha Rocio
    Marquez-Pedroza, Jazmin
    Sanchez-Rosales, Nayeli Alejandra
    Garcia-Rivera, Jose de Jesus
    Kobayashi-Gutierrez, Antonio
    Torres-Mendoza, Blanca Miriam
    Chavarria-Avila, Efrain
    Montano-Serrano, Raul Alejandro
    Cortes-Enriquez, Fernando
    Mireles-Ramirez, Mario Alberto
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
12345